#USA #Atrial Fibrillation #Bill Hoffman #Marseille #Volta Medical

Volta Medical Appoints Bill Hoffman as Executive Chairman

Volta Medical, a forefront player in health technology that specializes in artificial intelligence (AI) solutions aimed at aiding electrophysiologists, has recently made headlines with the appointment of Bill Hoffman as its new Executive Chairman of the Board. Hoffman's extensive experience in leading innovative startups, particularly as the former CEO of Inari Medical, underscores the strategic direction Volta Medical intends to pursue.

Hoffman's Remarkable Background

During his tenure at Inari Medical, Hoffman spearheaded the company's growth from a nascent startup to a publicly traded entity, achieving revenues exceeding $500 million. This trajectory culminated in a significant milestone when Inari was acquired by Stryker for $4.9 billion in February 2025. Such accomplishments signal Hoffman's capability in driving technological advancements and scaling businesses effectively in the medical field.

Théophile Mohr-Durdez, the CEO and co-founder of Volta Medical, expressed enthusiasm about Hoffman's new role, stating, "Bill's expertise in creating, marketing, and enhancing revolutionary medical technologies will be invaluable in accelerating our AI-based solutions for cardiac ablation to a global audience." This highlights Volta Medical's commitment to improving patient outcomes through innovative technology.

The Vision Moving Forward

Hoffman himself shared his excitement regarding the new position, emphasizing the significant clinical improvements achieved through Volta's AI technology in the realm of cardiac ablation, particularly for those suffering from atrial fibrillation (AF). He noted, "The technology developed by Volta has demonstrated, for the first time in history, a clinically significant improvement in outcomes for patients with atrial fibrillation." His optimistic view reflects a deep commitment not only to the company’s future but also to the health of millions affected by AF.

In addition to Hoffman's appointment, Volta's Board has also appointed Dr. Jerome Kalifa as Executive Vice President, who will maintain his role as Chief Medical Officer. Dr. Kalifa emphasized the collaborative mission to eliminate atrial fibrillation for as many patients as possible, indicating a strong dedication to addressing this prevalent health issue.

Recent Breakthroughs in Research

This leadership change comes at a crucial time, following the publication of the groundbreaking TAILORED-AF clinical trial in Nature Medicine. The trial showcased the efficacy of an AI-guided procedure that, when combined with conventional pulmonary vein isolation, significantly improved outcomes for patients with persistent atrial fibrillation. Such advancements emphasize the potential impact of Volta's technology in real-world medical applications and treatment protocols.

Understanding Atrial Fibrillation

Atrial fibrillation, as defined by the American Heart Association (AHA), entails an irregular heartbeat that can lead to severe complications such as stroke, blood clots, and heart failure. With approximately 33 million individuals across the globe living with this condition, the stakes are incredibly high. Alarmingly, untreated AF doubles the risk of heart-related deaths and significantly increases the likelihood of strokes, yet a staggering number of patients are unaware of the risks or lack proper treatment.

About Volta Medical

Founded in 2016 in Marseille, France, Volta Medical offers innovative AI-driven software solutions that support cardiac electrophysiologists during arrhythmia treatment procedures. The company's mission is to enhance arrhythmia management through cutting-edge medical devices and data-derived insights. The Volta AF-Xplorer™, for instance, is designed to assist cardiologists by providing real-time identification of abnormal electrograms during AF and atrial tachycardia procedures. Notably, the solution has achieved FDA 510(k) clearance and CE marking in Europe, underscoring its credibility and potential impact on patient care.

With the new leadership in place and groundbreaking innovations underway, Volta Medical is poised to lead the charge in combatting atrial fibrillation while improving the lives of countless patients around the world.

For those looking to learn more, visit AI for Persistent AF Care.